ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Evive Biotech meets primary and secondary endpoints in global Phase III clinical trial for their novel chemotherapy-induced neutropenia treatment
July 08, 2020Evive Biotech, a global biologics company developing novel biological therapies, is delighted to announce that its pivotal Phase III study (NCT03252431) for F-627 (efbemalenograstim alpha) to treat chemotherapy-induced neutropenia (CIN) in breast cancer
Pharma Sources Insight January 2025
